Elias Jabbour, MD
Professor of Medicine, Department of Leukemia, Division of Cancer MedicineMD Anderson Cancer CenterElias Jabbour, MD, joined the MD Anderson Cancer Center faculty in 2007 and is currently a professor of medicine in the Department of Leukemia, Division of Cancer Medicine. He is actively involved in developmental therapeutics research in leukemia. Over the past five years he has assisted in developing chemotherapeutic and biologic agents in leukemias and contributed to the development of others, including hypomethylating agents in AML and MDS, tyrosine kinase therapy in CML, and triple therapy in AML.
His research has provided insight into the biology of leukemias, and he has extensively addressed the question of resistance to tyrosine kinase inhibitors analyzing the outcome of these patients.
Disclosures: Dr. Jabbour received research grants from AbbVie, Adaptive Biotechnologies, Amgen, Pfizer, and Takeda; and consultancy fees from AbbVie, Adaptive Biotechnologies, Amgen, Bristol Myers Squibb, Genentech, Incyte, Novartis, Pfizer, and Takeda.
